Darbepoetin alfa
- Generic Name
- Darbepoetin alfa
- Brand Names
- Aranesp
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 209810-58-2
- Unique Ingredient Identifier
- 15UQ94PT4P
- Background
Human erythropoietin with 2 aa substitutions to enhance glycosylation (5 N-linked chains), 165 residues (MW=37 kD). Produced in Chinese hamster ovary (CHO) cells by recombinant DNA technology.
- Indication
For the treatment of anemia (from renal transplants or certain HIV treatment)
- Associated Conditions
- Anemia
- Associated Therapies
- -
Efficacy Study: Darbepoetin Alfa for the Treatment of Anemia in Patients With Chronic Kidney Disease
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2008-02-28
- Lead Sponsor
- Amgen
- Target Recruit Count
- 446
- Registration Number
- NCT00121602
Treatment for Patients With Gynecological Malignancies Who Suffer From Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-07-21
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00121030
Treatment for Anemic Subjects With Non-Myeloid Malignancies Receiving Chemotherapy
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2009-03-25
- Lead Sponsor
- Amgen
- Target Recruit Count
- 204
- Registration Number
- NCT00120705
Treatment for Patients Suffering From Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00120692
Treatment for Patients With Non-Small Cell Lung Cancer Who Developed Anemia Due to Chemotherapy
Phase 2
Completed
- Conditions
- First Posted Date
- 2005-07-19
- Last Posted Date
- 2007-12-24
- Lead Sponsor
- Amgen
- Registration Number
- NCT00120679
Darbepoetin Alfa Treatment of Anemia in Hemodialysis Subjects
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00119587
A Study of Subjects With Previously Untreated Extensive-Stage Small-Cell Lung Cancer (SCLC) Treated With Platinum Plus Etoposide Chemotherapy With or Without Darbepoetin Alfa
- First Posted Date
- 2005-07-14
- Last Posted Date
- 2008-08-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 600
- Registration Number
- NCT00119613
A Study of Darbepoetin Alfa for the Treatment of Anemia in Subjects With a Non-Myeloid Malignancy
Phase 3
Completed
- Conditions
- First Posted Date
- 2005-07-08
- Last Posted Date
- 2007-12-28
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117624
Impact of Darbepoetin Alfa on Exercise Tolerance and Left Ventricular Structure in Subjects With Symptomatic Congestive Heart Failure (CHF) and Anemia
Not Applicable
Completed
- Conditions
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2010-12-03
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117234
A Study of Repeat-Dose Subcutaneous Darbepoetin Alfa in Subjects With Congestive Heart Failure and Anemia, and a Single Dose in Healthy Age- and Sex-Matched Control Subjects
Phase 1
Completed
- Conditions
- First Posted Date
- 2005-07-06
- Last Posted Date
- 2009-10-16
- Lead Sponsor
- Amgen
- Registration Number
- NCT00117247
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath